A Umbrella Study in Relapsed/Refractory Peripheral T-cell Lymphoma Guided by Molecular Subtypes
Latest Information Update: 10 Nov 2022
At a glance
- Drugs Azacitidine (Primary) ; Camrelizumab (Primary) ; Dasatinib (Primary) ; Linperlisib (Primary) ; Rivoceranib (Primary) ; SHR-2554 (Primary) ; Tucidinostat (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 05 Oct 2022 New trial record